I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Multiple Sclerosis Research Program

Investigator-Initiated Research Award

Announcement Type: Initial

Funding Opportunity Number: HT942524MSRPIIRA

Assistance Listing Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application (Preproposal) Submission Deadline: 5:00 p.m. Eastern time (ET), June 10, 2024
- Invitation to Submit an Application: July 2024
- Application Submission Deadline: 11:59 p.m. ET, October 7, 2024
- End of Application Verification Period: 5:00 p.m. ET, October 14, 2024
- Peer Review: December 2024
- Programmatic Review: January 2025

This program announcement must be read in conjunction with the General Application Instructions, version 901. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

## I. OVERVIEW OF THE FUNDING OPPORTUNITY

- Section 1.1: Program Description
- Section 1.2: FY24 MSRP Investigator-Initiated Research Award Focus Areas
- Section 1.3: Award History

## II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

- Section 2.1: Program Description
  - Subsection 2.1.1: FY24 MSRP Investigator-Initiated Research Award Focus Areas
  - Subsection 2.1.2: Award History
- Section 2.2: Award Information
- Section 2.3: Eligibility Information
  - Subsection 2.3.1: Eligible Applicants
  - Subsection 2.3.2: Cost Sharing
  - Subsection 2.3.3: Other
- Section 2.4: Application and Submission Information
  - Subsection 2.4.1: Location of Application Package
  - Subsection 2.4.2: Content and Form of the Application Submission
    - Step 1: Pre-Application Submission
    - Step 2: Full Application Submission
    - Applicant Verification of Full Application Submission in eBRAP
  - Subsection 2.4.3: Unique Entity Identifier (UEI) and System for Award Management (SAM)
  - Subsection 2.4.4: Submission Dates and Times
  - Subsection 2.4.5: Funding Restrictions
  - Subsection 2.4.6: Other Submission Requirements
- Section 2.5: Application Review Information
  - Subsection 2.5.1: Criteria
  - Subsection 2.5.2: Application Review and Selection Process
  - Subsection 2.5.3: Integrity and Performance Information
- Section 2.6: Federal Award Administration Information
  - Subsection 2.6.1: Federal Award Notices
  - Subsection 2.6.2: PI Changes and Award Transfers
  - Subsection 2.6.3: Administrative and National Policy Requirements
  - Subsection 2.6.4: Reporting
- Section 2.7: Federal Awarding Agency Contacts
  - Subsection 2.7.1: eBRAP Help Desk
  - Subsection 2.7.2: Grants.gov Contact Center
- Section 2.8: Other Information
  - Subsection 2.8.1: Program Announcement and General Application Instructions Versions
  - Subsection 2.8.2: Administrative Actions
  - Subsection 2.8.3: Full Application Submission Checklist

## APPENDIX 1: ACRONYM LIST

- Appendix 1: ACRONYM LIST
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

The U.S. Army Medical Research Acquisition Activity (USAMRAA) is soliciting applications to the fiscal year 2024 (FY24) Multiple Sclerosis Research Program (MSRP) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC) is the program management agent for this funding opportunity. Congress initiated the MSRP in 2009 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the MSRP from FY09 through FY23 totaled $133.1 million (M). The FY24 appropriation is $20M.

*The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.*

II.A.1. FY24 MSRP Investigator-Initiated Research Award Focus Areas

To meet the intent of the funding opportunity, all applications submitted to the FY24 MSRP Investigator-Initiated Research Award (IIRA) program announcement *must* address one or more of the following Focus Areas:

- **Central Nervous System Repair, Protection, and Regenerative Potential in MS**

  Supports innovative mechanistic studies and translational approaches to promote axonal protection, regeneration, or remyelination in MS and/or relevant experimental models of demyelination. Examples of acceptable studies include, but are not limited to:

  - Obstacles to repair and approaches to overcome and achieve remyelination. Factors to be considered include extrinsic or intrinsic factors (e.g., mechanical, sex, aging, inhibitory signaling), trophic and inhibitory factors, and lifestyle factors.

  - Cell-cell interactions within the central nervous system.

  - Epigenetic regulation of cells within the central nervous system.

  - Drugs, biologics, and cell-based therapies that target the central nervous system.

  - Identification of factors that promote protection and repair.

  - Innate immune-mediated mechanisms within the central nervous system.

  - Development of imaging and non-imaging outcome measures of repair.

  - Development of new models that reflect disease progression.
Note: Studies addressing developmental myelination, dysmyelination, basic mechanisms of demyelination, or peripheral immunomodulatory therapeutic strategies that limit tissue injury secondarily will not be considered for funding.

- Correlates of Disease Activity and Progression in MS

Supports studies to identify and/or validate correlates of disease activity and progression using pre-existing specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered patient cohorts.

- Examples of acceptable cohorts for study include controlled clinical trials, observational studies, and registries.

- Analyses may utilize existing clinical data and outcome measures, specimens, and/or imaging data.

- Correlates include clinical outcome measures, patient self-reported measures, and imaging and non-imaging biomarkers.

- Careful consideration should be given to potential confounders in the study population (e.g., disease-modifying therapies).

Inclusion of information regarding the quality of the specimens, replication plan, assay validation, or context of use will be given special consideration.

Note: The study must leverage pre-existing specimens and/or data that are available at the time of application submission; ongoing specimens and/or data collection from participants in the pre-existing cohort is allowed. However, the collection of new set of specimens and/or data or recruitment of new subjects is not permitted.

- Biology and Measurement of MS Symptoms

Supports studies of MS symptoms, which may include pain, fatigue, depression, anxiety, incontinence, impaired mobility, and cognitive, motor, visual, or sexual dysfunction, etc. Examples of acceptable studies include, but are not limited to, the following:

- Mechanisms underlying symptoms of MS.

- Development of measurements for future interventional studies to alleviate symptoms.

- Development and/or validation of outcome measures and tools for symptoms including wearables and/or remote data capture.

- Observational studies on the prevalence or significance of symptoms including the contribution of comorbidities, lifestyle behaviors, and health disparities. Careful consideration should be given to potential confounders in the study population (e.g., disease-modifying therapies), controls, and/or accurate measures of symptoms.
Note: Studies of disease-modifying therapies that secondarily impact MS symptoms will not be considered for funding under this Focus Area.

- **Mechanisms Contributing to or Associated with MS Etiology, Prodrome, Onset, and Disease Course**

  Supports studies to identify various factors and their roles in MS etiology, prodrome, onset, activity, disease worsening, and progression. Examples of factors include, but are not limited to, the following:
  
  - Infections (such as Epstein-Barr Virus and SARS-CoV-2) and/or vaccines
  - CNS innate immunity and compliment activation
  - Genetics and/or epigenetics
  - Environment
  - Comorbidities
  - Health behaviors
  - Demographics (including, but not limited to, sex, gender, race, ethnicity, age)
  - Socioeconomics and access to care.

**II.A.2. Award History**

The MSRP IIRA mechanism was first offered in FY15. Since then, 301 IIRA applications have been received, and 57 have been recommended for funding. The overall funding rate is 19%.

**II.B. Award Information**

The MSRP IIRA supports highly rigorous, high-impact research projects that have the potential to make an important contribution to MS research, patient care, and/or quality of life. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, clinical trial results, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. **Applications must include preliminary and/or published data that are relevant to MS and the proposed research project.**

For the “Correlates of Disease Activity and Progression in MS” Focus Area, applications must demonstrate access to the relevant specimens and/or data of the proposed cohort. Refer to **Attachment 8: Letter(s) Confirming Access to Specimens and/or Data** for more details.

**Note for projects involving animal models of MS:** Applicants should be prudent in the choice of animal model(s) for their proposed research project. Applicants must justify the relevance of their proposed animal model(s) to the specific aspect of human MS to be studied.
New Investigator option: The FY24 MSRP IIRA mechanism encourages applications from investigators in the early stages of their MS research career. The New Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments. Applications from Established Investigators and New Investigators will be peer and programmatically reviewed in separate groups. Principal Investigators (PIs) applying under the New Investigator option are encouraged to strengthen their applications through collaboration with investigators experienced in MS research and/or possess other relevant expertise as demonstrated by a record of funding and publications.

Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.

The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.

Clinical trials are not allowed under this Funding Opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:

1. Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.

2. Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.

3. Outcomes research and health services research that do not fit under the definition of clinical trial.
Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.

The funding instrument for awards made under the FY24 MSRP IIRA program announcement will be grants (31 USC 6304).

The anticipated total costs budgeted for the entire period of performance for an FY24 MSRP IIRA Award should not exceed $1.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Awards supported with FY24 MSRP funds will be made no later than September 30, 2025.

*The CDMRP expects to allot approximately $6M to fund approximately six Investigator Initiated Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.*

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization:

Extramural and Intramural organizations are eligible to apply, including foreign or domestic organizations, for-profit and non-profit organizations, and public entities.

**Extramural Organization:** An eligible non-Department of Defense (DOD) organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD (i.e., intragovernmental organizations), and research institutes.

**Intramural DOD Organization:** Refers specifically to DOD organizations including DOD laboratories, DOD military treatment facilities, and/or DOD activities embedded within a civilian medical center.

Awards are made to eligible organizations, not to individuals. Refer to the General Application Instructions, Appendix 1, for additional recipient qualification requirements.

II.C.1.b. Principal Investigator

*Although a PI may be eligible for both the Established Investigator and New Investigator options, only one may be chosen at the time of pre-application submission; the choice of application option is at the PI’s discretion.*
• **Established Investigator**
  - The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

• **New Investigator**
  - At the application submission deadline, the PI must be an independent investigator at the level of Assistant Professor (or equivalent) and within no more than 5 years from the start of their faculty position (excluding time spent in residency, fellowship, or on family medical leave); and must not have received more than $300,000 in total direct costs for previous or concurrent MS research as a PI of one or more non-mentored, peer-reviewed grant(s) from any agency.

The CDMRP strongly encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at https://orcid.org/.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

**II.C.2. Cost Sharing**

Cost sharing/matching is not an eligibility requirement.

**II.C.3. Other**

Organizations must be able to access .gov and .mil websites to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

Refer to [Section II.H.2, Administrative Actions](#), for a list of administrative actions that may be taken if a pre-application or full application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

**II.D. Application and Submission Information**

**II.D.1. Location of Application Package**

Submission is a two-step process requiring both a pre-application submitted via the Electronic Biomedical Research Application Portal (eBRAP.org) and a full application (eBRAP.org or Grants.gov). Depending on the type of submission (i.e., extramural versus intramural), certain aspects of the submission process will differ.

The CDMRP uses two portal systems to accept pre- and full application submissions.

**eBRAP** ([https://ebrap.org](https://ebrap.org)) is a secure web-based system that allows PIs and/or organizational representatives from both extra- and intramural organizations to receive communications from the CDMRP and submit their pre-applications. Additionally, eBRAP allows extramural
applicants to view and verify full applications submitted to Grants.gov and allows intramural DOD applicants to submit and verify full applications following their pre-application submission.

Grants.gov (https://grants.gov) is a federal system that must be used by funding agencies to announce extramural grant applications. Full applications for CDMRP funding opportunities can only be submitted to Grants.gov after submission of a pre-application through eBRAP.

**Application Submission Workflow**

**Extramural Submission:** An application submitted by an extramural organization for an extramural or intramural PI working within an extramural or intramural organization. For example, a research foundation submitting an application for a DOD employee working within a DOD organization would be considered an extramural submission and should follow instructions specific to extramural submissions. Download application package components for HT942524MSRPIIRA from Grants.gov (https://grants.gov). Full applications from extramural organizations **must** be submitted through Grants.gov.

**Intramural Submission:** An application submitted by an intramural DOD organization for an investigator employed by that organization. Intramural DOD organizations may submit full applications to either eBRAP or Grants.gov. Download application package components for HT942524MSRPIIRA from the anticipated submission portal eBRAP (https://ebrap.org) or Grants.gov.

The submission process should be started early to avoid missing deadlines. Regardless of submission type or portal used, all pre- and full application components must be submitted by the deadlines stipulated on the first page of this program announcement. There are no grace periods
for deadlines; failure to meet submission deadlines will result in application rejection. *The USAMRAA cannot make allowances/exceptions for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

II.D.2. Content and Form of the Application Submission

*Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).*

Unnecessary duplication of funding, or accepting funding from more than one source for the same research, is prohibited. See the CDMRP’s full position on research duplication at [https://cdmrp.health.mil/funding/researchDup](https://cdmrp.health.mil/funding/researchDup).

Including classified research data within the application and/or proposing research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns, may result in application withdrawal. Refer to the General Application Instructions, Appendix 7, Section B.

FY24 MSRP Programmatic Panel members should not be involved in any pre-application or full application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

II.D.2.a. Step 1: Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP ([https://eBRAP.org/](https://eBRAP.org/)).

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

When starting the pre-application, applicants will be asked to select a “Mechanism Option.” Please be sure to select the correct option appropriate to your pre-application:

<table>
<thead>
<tr>
<th>Application Includes:</th>
<th>Select Option:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established Investigator</td>
<td>Investigator-Initiated Research Award - Established Investigator (IIRA-EI)</td>
</tr>
<tr>
<td>New Investigator</td>
<td>Investigator-Initiated Research Award - New Investigator (IIRA-NI)</td>
</tr>
</tbody>
</table>
II.D.2.a.i. Pre-Application Components

Pre-application submissions must include the following components (refer to the General Application Instructions, Section III.B, for additional information on pre-application submission):

*Note: Upload documents as individual PDF files unless otherwise noted.*

- **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  o **Research Idea**
    - State which FY24 MSRP IIRA Focus Areas the proposed research project will address. *Clearly describe how the proposed research directly addresses one or more of the FY24 MSRP IIRA Focus Areas.*
    - State the project’s hypothesis, objectives, rationale, and specific aims. Describe the rationale, methodology, and experimental design to test the hypothesis and the specific aims of the project. Demonstrate how the research is based on preliminary data relevant to the proposed research.
    - If applicable, state each animal model of MS to be used and explain its relevance to the specific aspect of human MS to be studied.

  o **Impact**
    - Describe the potential short-term and long-term outcomes of the proposed research on one or more of the FY24 MSRP IIRA Focus Areas.

  o **Personnel**
    - Describe how the PI meets the eligibility requirements.

- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application must be uploaded as individual files and are limited to the following:

  o **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
II.D.2.a.ii  Pre-Application Screening Criteria

To determine the technical merits of the pre-application and the relevance to the mission of the Defense Health Program (DHP) and the MSRP, pre-applications will be screened based on the following criteria:

○ Research Idea
  –  To what extent the proposed research directly addresses one or more of the FY24 MSRP IIRA Focus Areas.
  –  Whether the rationale, methodology, and experimental design will test the hypothesis and support the specific aims of the project. How well the preliminary data support the hypothesis and specific aims of the project.
  –  If applicable, to what extent each proposed animal model of MS is relevant to the specific aspect of human MS to be studied.

○ Impact
  –  To what extent the proposed research may lead to promising short-term and long-term impact on one or more of the FY24 MSRP IIRA Focus Areas.

○ Personnel
  –  Whether the PI meets the eligibility requirements.

II.D.2.a.iii  Notification of Pre-Application Screening Results

Following the pre-application screening, PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in Section I, Overview of the Funding Opportunity. No feedback (e.g., a critique of the pre-application’s strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.
II.D.2.b. Step 2: Full Application Submission

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (https://grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations.

II.D.2.b.i. Full Application Submission Type

Extramural Submissions: Full applications from extramural organizations must be submitted through Grants.gov Workspace. Full applications from extramural organizations, including non-DOD federal organizations, received through eBRAP will be withdrawn. Refer to the General Application Instructions, Section IV, for considerations and detailed instructions regarding extramural full application submission.

Intramural Submissions: Intramural DOD organizations may submit full applications through either eBRAP or Grants.gov. There is no preference from the CDMRP for which submission portal is utilized; submission through one portal or the other does not provide the application any advantage during the review process. Intramural DOD organizations that choose to submit through Grants.gov should follow Extramural Submission instructions. Intramural DOD organizations that are unable to submit through Grants.gov should submit through eBRAP. For the remainder of this program announcement, it will be assumed intramural DOD submissions will proceed through eBRAP. Refer to the General Application Instructions, Section V, for considerations and detailed instructions regarding intramural DOD full application submission.

II.D.2.b.ii. Full Application Submission Components

Each application submission must include the completed full application package for this program announcement. See Section II.H.3 of this program announcement for a checklist of the required application components.

(a) SF424 Research & Related Application for Federal Assistance Form (Extramural Submissions Only): Refer to the General Application Instructions, Section IV.B, for detailed information.

(b) Attachments:

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 2.
Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf”. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information that expands the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below:

- **Background:** Describe the problem, question, or knowledge gap related to one or more of the FY24 MSRP IIRA Focus Areas to be addressed by the proposed research. **Clearly describe how the proposed research project directly addresses one or more of the FY24 MSRP IIRA Focus Areas.** Present the ideas and scientific rationale behind the proposed research project. Include relevant literature citations and preliminary and/or published data relevant to MS and the proposed research project. Describe how the previous experience of the PI and research team relates to the proposed research project.

- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.

- **Specific Aims:** Concisely explain the proposed research project’s specific aims.

- **Research Strategy and Feasibility:**
  
  - **For all Focus Areas, the following criteria apply:**
    
    - Describe the experimental design, methods, and analyses, including appropriate randomization, blinding, and controls, and how they will achieve reproducible and rigorous results.
    
    - Describe how data will be collected, handled, and analyzed in a manner that is consistent with the study objectives. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study.
    
    - Describe the statistical analysis plan appropriate for the proposed research project.
    
    - If applicable, describe how the analysis will account for potential confounding factors in the study population (e.g., disease-modifying treatments).
    
    - Address potential problem areas and present alternative methods and approaches.
    
    - If any biological material will be used in the proposed studies, provide the type and source of the material.
If human subjects or human anatomical samples will be used, include a detailed plan for the acquisition of samples.

If applicable, submit an Animal Research Plan (Attachment 7) and justify the relevance of the proposed animal model(s) to MS in humans.

If applicable, describe how the symptom(s) studied will be verified.

**In addition, for research addressing the “Correlates of Disease Activity and Progression in MS” Focus Area:**

- Describe the proposed pre-existing cohort, including the type of specimens and/or data available.
- Describe the size of the pre-existing cohort, including the intervention and control groups, and the expected statistical power of the study.
- Explain how the cohort is appropriate for the study objective.
- State when subject accrual and data/sample acquisition ended for the cohort.
- If applicable, describe any additional specimens and/or data to be collected from participants in the pre-existing cohort at one additional time point and the value these specimens and/or data will add to the research.
- If applicable, outline the recruitment process for previous participants in the cohort. Estimate the likely rates of recruitment, enrollment, and completion, and the expected statistical power of the results obtained from these additional data.
- Outline plans and opportunities for eventual validation and independent replication of results in follow-up studies.

**In addition, for clinical research, describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, racial, and ethnic group, and an accompanying rationale for the selection of subjects.**

**New Investigators:** Collaboration with investigators experienced in MS research and/or possessing other relevant expertise is encouraged. If applicable, describe the specific contributions of the collaborator(s) to the research project. The application should describe how the collaboration(s) will augment the PI’s expertise to best address the research question. All New Investigator option applicants must meet specific eligibility criteria as described in Section II.C.1.b, Principal Investigator.

- **Attachment 2: Supporting Documentation:** Combine and upload as a single file named “Support.pdf”. Start each document on a new page. The Supporting
Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited (including URLs, if available) in the Project Narrative using a standard reference format.

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.

- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- **Letters of Organizational Support:** Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.

- **Letters of Collaboration (if applicable):** Provide a signed letter from each collaborating individual and/or organization demonstrating that the PI has the support and resources necessary for the proposed work. If an investigator at an intramural DOD organization is named as a collaborator on a full application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural DOD organization authorizing the collaborator’s involvement.

- **Intellectual Property:** Information can be found in the 2 CFR 200.315, “Intangible Property.”

- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Commercialization Strategy (if applicable):** Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

- **DOD Data Management Plan (two-page limit is recommended):** Describe the data management plan in accordance with Section 3.c, Enclosure 3, DoD Instructions 3200.12. *Do not duplicate the Data and Research Resources Sharing Plan.* Refer to General Application Instructions, Section IV.B, Attachments Form, Attachment: Supporting Documentation, for detailed information regarding Data Management Plan content.

- **Data and Research Resources Sharing Plan:** Describe the type of data or research resource to be made publicly available as a result of the proposed work. Describe how data and resources generated during the performance of the project will be shared with the research community. Include the name of the repository(ies) where scientific data and resources arising from the project will be archived, if applicable. If a public repository will not be used for data or resource sharing, provide justification. Provide a milestone plan for data/results dissemination including when data and resources will be made available to other users, including dissemination activities with a particular focus on feeding back the data to affected communities and/or research participants. Refer to the CDMRP Policy on Data & Resource Sharing located on the eBRAP “Funding Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm) for more information about the CDMRP’s expectations for making data and research resources publicly available.

- **Use of DOD Resources (if applicable):** Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active-duty military populations and/or DOD resources or databases.

- **Use of U.S. Department of Veterans Affairs (VA) Resources (if applicable):** Provide a letter of support signed by the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. If the VA-affiliated non-profit corporation is not identified as the applicant organization for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

  o **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. *Abstracts of all funded research projects will be posted publicly.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.
Technical abstracts should be written using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** State the [FY24 MSRP IIRA Focus Area(s)](#) to be addressed. *Describe how the proposed research project directly addresses one or more of the Focus Areas.* Present the ideas and reasoning behind the proposed research project.

- **Hypothesis/Objective:** State the hypothesis to be tested or the objective to be reached. Provide evidence or rationale that supports the hypothesis/objective.

- **Specific Aims:** State the specific aims of the proposed research project.

- **Study Design:** Describe the study design including appropriate controls.

- **Impact:** Explain how the proposed research project will produce results that are likely to translate, whether in the short term or long term, into advancing MS research, patient care, and/or quality of life.

  ○ **Attachment 4: Lay Abstract (one-page limit):** Upload as “LayAbs.pdf”. The lay abstract is used by all reviewers, and addresses issues of particular interest to the affected community. *Abstracts of all funded research projects will be posted publicly.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. *Do not duplicate the technical abstract.*

Lay abstracts should address the points outlined below *in a manner that will be readily understood by readers without a background in science or medicine.* Avoid the overuse of scientific jargon, acronyms, and abbreviations. The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer community.

- Summarize the objectives and rationale for the proposed research.

- State the [FY24 MSRP IIRA Focus Area(s)](#) the proposed project addresses. *Describe how the proposed research project directly addresses one or more of the FY24 MSRP IIRA Focus Areas.*

- Describe the applicability of the research to advance MS patient care:
  - What population will the research help, and how will it help them?
  - What are the potential applications, benefits, and risks of the anticipated outcomes?
  - What are the likely contributions of the proposed research project toward advancing research, patient care, and/or quality of life?
If the research is too basic for short-term clinical applicability, describe how the outcomes of the proposed project will advance the field of MS research.

○ **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf”. Refer to the eBRAP “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)) for the suggested SOW format and recommended strategies for assembling the SOW.

For the FY24 MSRP IIRA, refer to “Example: Assembling a Generic Statement of Work for guidance on preparing the SOW. Use the “Suggested SOW Format” to develop the SOW for the proposed research. Submit the SOW as a PDF file.

○ **Attachment 6: Impact Statement (one-page limit):** Upload as “Impact.pdf”.

Explain why the proposed research project is important and the impact it will have on one or more of the [FY24 MSRP IIRA Focus Areas](#). Describe the potential impact(s) under two separate headings:

- **Short-term impact:** Detail the anticipated outcome(s) that will be directly attributed to the results of the proposed research project related to one or more of the FY24 MSRP IIRA Focus Areas.

- **Long-term impact:** Explain the anticipated long-term gains from the proposed research project, including how the new understanding will ultimately contribute toward the goal of advancing MS research, patient care, and/or quality of life related to one or more of the FY24 MSRP IIRA Focus Areas.

○ **Attachment 7: Animal Research Plan (three-page limit) (only required if proposed research project involves animals):** Upload as “AnimalPlan.pdf”.

When the proposed study involves animals, the applicant is required to submit a summary describing the animal research that will be conducted. Applicants should not submit a verbatim replica of the protocol(s) to be submitted to the Institutional Animal Care and Use Committee (IACUC) as the Animal Research Plan. The Animal Research Plan should address the following points for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.

- Explain why the proposed model(s) is superior to other available animal models for the proposed research strategy.

- Summarize the procedures to be conducted. Describe how the study will be controlled.

- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal
treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.

- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.

- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

- **Attachment 8: Letter(s) Confirming Access to Specimens and/or Data, if applicable:** Upload as “Access.pdf”. If the application addresses the Focus Area of “Correlates of Disease Activity and Progression in MS,” or if the application addresses more than one Focus Areas and one of them is “Correlates of Disease Activity and Progression in MS,” provide a confirmation letter signed by the appropriate Institution Official who has the authority to confirm access to the proposed cohort specimens and/or data necessary to carry out the study.

The study must leverage **pre-existing** specimens and/or data that are available at the time of application submission; ongoing specimens and/or data collection from participants in the pre-existing cohort is allowed. However, the **collection of new sets of specimens and/or data or the recruitment of new subjects is not permitted.**

- **Attachment 9: (New Investigator option only) Eligibility Statement (one-page limit):** Upload as “Eligibility.pdf”. Provide a letter signed by the Department Chair, Division Chief, or equivalent official, verifying that the eligibility requirements will be met on the application submission deadline. The letter should verify that the PI is an independent investigator at the level of Assistant Professor (or equivalent), with no more than 5 years from the start of their independent faculty position (excluding time spent in residency, fellowship, or on family medical leave), and has not received more than $300,000 in total direct costs for previous or concurrent MS research as a PI of one or more non-mentored, peer-reviewed grant(s) from any agency. (Refer to Section II.C.1.b, Principal Investigator, for eligibility information).

- **Attachment 10: Representations (Extramural Submissions Only):** Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)). For more information, see the General Application Instructions, Appendix 8, Section B, Representations.

- **Attachment 11: Suggested Intragovernmental/Intramural Budget Form (if applicable):** Upload as “IGBudget.pdf”. If an intramural DOD organization will be a collaborator in the performance of the project, complete a separate budget using the “Suggested Intragovernmental/Intramural Budget Form”, available for download on the eBRAP “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)). The budget should cover the entire period of performance for each intramural DOD site and include a budget justification as
instructed. The total costs per year for each subaward (direct and indirect costs) should be included on the Grants.gov Research & Related Budget Form under Subaward Costs. Refer to the General Application Instructions, Section V.A.(e), for additional information and considerations.

(c) **Research & Related Personal Data:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(c); and for intramural submissions, refer to the General Application Instructions, Section V.A.(c), for detailed instructions.

(d) **Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions, refer to the General Application Instructions, Section IV.B.(d); and for intramural submissions, refer to the General Application Instructions, Section V.A.(d), for detailed instructions.

  - **PI Biographical Sketch (five-page limit):** Upload as “Biosketch_LastName.pdf”.
  - **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.
  - **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch_LastName.pdf”.
  - **Key Personnel Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.

(e) **Research & Related Budget:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(e); and for intramural submissions, refer to the General Application Instructions, Section V.A.(e), for detailed instructions.

  - **Budget Justification (no page limit):** For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), Section L, for instructions. For intramural submissions, refer to General Application Instructions, Section V.A.(e), Budget Justification Instructions.

(f) **Project/Performance Site Location(s) Form:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(f); and for intramural submissions, refer to the General Application Instructions, Section V.A.(f), for detailed instructions.

(g) **Research & Related Subaward Budget Attachment(s) Form (if applicable, Extramural Submissions Only):** Refer to the General Application Instructions, Section IV.B.(g), for detailed instructions.

  - **Extramural Subaward:** Complete the Research & Related Subaward Budget Form and upload through Grants.gov.

  - **Intramural DOD Subaward:** Complete a separate “Suggested Intragovernmental/Intramural Budget Form” for each intramural DOD subaward and upload as a single document titled IGBudget.pdf to Grants.gov as Attachment 11.
**II.D.2.c. Applicant Verification of Full Application Submission in eBRAP**

Independent of submission type, once the full application is submitted it is transmitted to and processed in eBRAP. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log into eBRAP to review, modify, and verify the full application submission. Verification is strongly recommended but not required. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in the “Full Application Files” tab in eBRAP. However, eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the full application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the end of the application verification period. The full application cannot be modified once the application verification period ends.

**II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)**

The applicant organization must be registered as an entity in SAM ([https://www.sam.gov/content/home](https://www.sam.gov/content/home)) and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the UEI generated by SAM in applications to this funding opportunity.

**II.D.4. Submission Dates and Times**

The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity.

**II.D.5. Funding Restrictions**

The maximum period of performance is 3 years. ***The period of performance is not to exceed 4 years.***

The application’s total costs budgeted for the entire period of performance should not exceed **$1M.** If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.
For this award mechanism, the applicant may request direct costs for (not all-inclusive):

- Costs for one investigator to travel to one scientific/technical meeting per year to present project information or disseminate project results from the FY24 MSRP IIRA.

Must not be requested for:

- Clinical trial costs.

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be individually evaluated according to the following **scored criteria**, which are listed in **decreasing** order of importance:

- **Research Strategy and Feasibility**
  
  o **For all Focus Areas**
  
    - *To what extent the proposed research directly addresses one or more of the FY24 MSRP IIRA Focus Areas.*
    
    - How well the preliminary data and scientific rationale support the proposed research project.
    
    - To what extent the proposed research project is feasible as described.
    
    - To what extent the statistical analysis plan is appropriate for the proposed research project.
    
    - How well the study is designed to achieve reproducible and rigorous results, including controls, sample size estimation, power analysis, blinding, randomization, and data handling.
    
    - If applicable, how well the analysis accounts for potential confounding factors in the study population (e.g., disease-modifying treatments).
    
    - For applications proposing prospective accrual of human subjects, the extent to which the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research.
– How well the application identifies potential problems and describes alternative approaches.

– If applicable, how well the proposed animal studies are designed to achieve the objectives, including the choice of model, the model’s relevance to MS in humans, and endpoints/outcome measures to be used.

– If applicable, how well the symptom(s) studied will be verified.

– In addition, for applications addressing the “Correlates of Disease Activity and Progression in MS” Focus Area, the following criteria also apply:
  
  ▪ How well the application demonstrates access to the proposed pre-existing cohort specimens and/or data.
  
  ▪ To what extent the proposed pre-existing cohort is appropriate for the objective of the study.
  
  ▪ To what extent the proposed pre-existing cohort is well-characterized and adequately controlled.
  
  ▪ To what extent the statistical power of the study is appropriate, given the size of the cohort.
  
  ▪ Whether subject accrual and sample/data acquisition for the pre-existing cohort was complete at the time of submission.
  
  ▪ If applicable, to what extent the plan to recruit previous participants in the cohort for follow-up studies is adequate.
  
  ▪ How well the application describes future plans and opportunities for validation or replication of results.

• Impact
  
  ○ To what extent the anticipated short-term outcomes will be directly attributed to the results of the proposed research project relate to one or more of the FY24 MSRP IIRA Focus Areas.
  
  ○ To what extent the anticipated long-term gains from the proposed research project, including how the new understanding will ultimately contribute to the goal of advancing MS research, patient care, and/or quality of life, relate to one or more of the FY24 MSRP IIRA Focus Areas.

• Personnel
  
  ○ To what extent the experience, expertise, and record of accomplishments of the PI and key personnel demonstrate their ability to successfully complete the proposed research project.
○ To what extent the levels of effort by the PI and other key personnel are appropriate to ensure the success of the proposed research project.

○ How the research team’s background and expertise are appropriate to accomplish the proposed work.

○ In addition, for the New Investigator option:
  – If applicable, to what extent the specific contributions of the collaborator(s) will augment the PI’s expertise to best address the research question.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed unscored criteria:

• Budget
  ○ Whether the budget is appropriate for the proposed research.

• Environment
  ○ To what extent the scientific environment is appropriate for the proposed research project.

  ○ How well the research requirements are supported by the availability of and accessibility to facilities and resources.

  ○ To what extent the quality and level of institutional support are appropriate for the proposed research project.

  ○ If applicable, to what degree the intellectual and material property plan is appropriate.

• Application Presentation
  ○ To what extent the writing, clarity, and presentation of the application components influence the review.

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

• Ratings and evaluations of the peer reviewers

• Relevance to the priorities of the DHP and FY24 MSRP, as evidenced by the following:
  ○ Adherence to the intent of the funding opportunity

  ○ Program portfolio composition
○ Programmatic relevance to one or more of the FY24 MSRP IIRA Focus Areas

○ Relative impact.

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at https://cdmrp.health.mil/about/2tierRevProcess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the review panel. Violations of confidentiality can result in the dissolution of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to a third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in SAM.

An applicant organization may review SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoD GARs), Section 22.415.
II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Each applicant organization and PI will receive email notification when the funding recommendations are posted to eBRAP. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the funding recommendation and review process for the MSRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program’s page within the CDMRP website.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).

Intra-DOD obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to intragovernmental and intramural DOD organizations will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD), or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOD investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), Pre-Award Costs section, and for intramural submissions, refer to the General Application Instructions, Section V.A.(e), Pre-Award Costs section, for additional information about pre-award costs.

If there are technical reporting requirement delinquencies for any existing CDMRP awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.

II.F.2. PI Changes and Award Transfers

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.
An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 7, Section F, for general information on organization or PI changes.

II.F.3. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 7, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 8, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the USAMRAA Research Terms and Conditions: Addendum to the DoD R&D Terms and Conditions for further information.

Applications recommended for funding that involve animals, human data, human specimens, human subjects, or human cadavers must be reviewed for compliance with federal and DOD animal and/or human subjects protection requirements and approved by the USAMRDC Office of Human and Animal Research Oversight, prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee, Institutional Review Board, or Ethics Committee review. Refer to the General Application Instructions, Appendix 6, for additional information.

II.F.4. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. *If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.*

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section.
The Award Expiration Transition Plan must outline whether and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

The Public Health Service (PHS) Inclusion Enrollment Reporting Requirement (only required for clinical research studies): Enrollment reporting on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to SAM about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 8, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. eBRAP Help Desk

Questions regarding program announcement content or submission requirements as well as technical assistance related to pre-application or intramural application submission:

Phone: 301-682-5507

Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions regarding Grants.gov registration and Workspace:

Phone: 800-518-4726; International 1-606-545-5035

Email: support@grants.gov

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 901a. The program announcement numeric version code will match the General Application Instructions version code 901.
II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur.

II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- For studies utilizing animal models, Attachment 7: Animal Research Plan is missing.
- For studies addressing the “Correlates of Disease Activity and Progression in MS” Focus Area, Attachment 8: Letter(s) Confirming Access to Specimens and/or Data is missing.
- Project Narrative is missing.
- Budget is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY24 MSRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation, including letters of support/recommendation. A list of the FY24 MSRP Programmatic Panel members can be found at https://cdmrp.health.mil/msrp/panels/panels24.
- The application fails to conform to this program announcement description.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
• Applications that include names of personnel from either of the CDMRP peer or programmatic review companies. For FY24, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.health.mil/about/2tierRevProcess).

• Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

• Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP.

• Applications submitted by a federal government organization (including an intramural DOD organization) may be withdrawn if (a) the organization cannot accept and execute the entirety of the requested budget in current fiscal year (FY24) funds; and/or (b) the federal government organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to collaborators.

• Application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.

• For the “Central Nervous System Repair, Protection, and Regenerative Potential in MS” Focus Area, the application is for a study addressing developmental myelination, dysmyelination, basic mechanisms of demyelination, or peripheral immunomodulatory therapeutic strategies that limit tissue injury secondarily.

• For the “Biology and Measurement of MS Symptoms” Focus Area, the application is for a study of disease-modifying therapies that secondarily impact MS symptoms.

• For the “Correlates of Disease Activity and Progression in MS” Focus Area, the application does not demonstrate access to the relevant specimens and/or data of the proposed cohort.

• The application proposes to use specimens and/or data that are fully dependent on new specimens and/or data.

• The application does not include preliminary and/or published data that are relevant to MS and the proposed research project.

• Submission of the same research project to different funding opportunities within the same program and fiscal year.

• The PI does not meet the eligibility criteria.

• The invited application proposes a different research project than that described in the pre-application.

• The application does not address one or more of the FY24 MSRP IIRA Focus Areas.
II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
II.H.3. Full Application Submission Checklist

<table>
<thead>
<tr>
<th>Full Application Components</th>
<th>Uploaded</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance</td>
<td></td>
</tr>
<tr>
<td><em>(Extramural submissions only)</em></td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2)</td>
<td></td>
</tr>
<tr>
<td><em>(Intramural submissions only)</em></td>
<td></td>
</tr>
<tr>
<td><strong>Attachments</strong></td>
<td></td>
</tr>
<tr>
<td>Project Narrative – Attachment 1, upload as “ProjectNarrative.pdf”</td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation – Attachment 2, upload as “Support.pdf”</td>
<td></td>
</tr>
<tr>
<td>Technical Abstract – Attachment 3, upload as “TechAbs.pdf”</td>
<td></td>
</tr>
<tr>
<td>Lay Abstract – Attachment 4, upload as “LayAbs.pdf”</td>
<td></td>
</tr>
<tr>
<td>Statement of Work – Attachment 5, upload as “SOW.pdf”</td>
<td></td>
</tr>
<tr>
<td>Impact Statement – Attachment 6, upload as “Impact.pdf”</td>
<td></td>
</tr>
<tr>
<td>Animal Research Plan – Attachment 7, upload as “AnimalPlan.pdf”</td>
<td></td>
</tr>
<tr>
<td><em>(if applicable)</em></td>
<td></td>
</tr>
<tr>
<td>Letter(s) Confirming Access to Specimens and/or Data – Attachment 8, upload as “Access.pdf” <em>(if applicable)</em></td>
<td></td>
</tr>
<tr>
<td>Eligibility Statement <em>(New Investigator option only)</em> – Attachment 9, upload as “Eligibility.pdf” <em>(if applicable)</em></td>
<td></td>
</tr>
<tr>
<td>Representations <em>(Extramural submissions only)</em> – Attachment 10, upload as “RequiredReps.pdf”</td>
<td></td>
</tr>
<tr>
<td>Suggested Intragovernmental/Intramural Budget Form – Attachment 11, upload as “IGBudget.pdf” <em>(if applicable)</em></td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Personal Data</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Senior/Key Person Profile (Expanded)</strong></td>
<td></td>
</tr>
<tr>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf)</td>
<td></td>
</tr>
<tr>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf)</td>
<td></td>
</tr>
<tr>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person</td>
<td></td>
</tr>
<tr>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person</td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Budget (Extramural submissions only)</strong></td>
<td></td>
</tr>
<tr>
<td>Include budget justification</td>
<td></td>
</tr>
<tr>
<td><strong>Budget (Intramural submissions only)</strong></td>
<td></td>
</tr>
<tr>
<td>Include budget justification</td>
<td></td>
</tr>
<tr>
<td><strong>Project/Performance Site Location(s) Form</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Research &amp; Related Subaward Budget Attachment(s) Form (if applicable)</strong></td>
<td></td>
</tr>
</tbody>
</table>
## APPENDIX 1: ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOS/R&amp;D</td>
<td>Associate Chief of Staff for Research and Development</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>DHP</td>
<td>Defense Health Program</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoDGARs</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>IACUC</td>
<td>Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>IIRA</td>
<td>Investigator-Initiated Research Award</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
</tr>
<tr>
<td>MSRP</td>
<td>Multiple Sclerosis Research Program</td>
</tr>
<tr>
<td>PDF</td>
<td>Portable Document Format</td>
</tr>
<tr>
<td>PHS</td>
<td>Public Health Service</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>RPPR</td>
<td>Research Performance Progress Report</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>UEI</td>
<td>Unique Entity Identifier</td>
</tr>
<tr>
<td>URL</td>
<td>Uniform Resource Locator</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRDC</td>
<td>U.S. Army Medical Research and Development Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>VA</td>
<td>U.S. Department of Veterans Affairs</td>
</tr>
</tbody>
</table>